The role of costimulatory molecules in glioma biology and immune microenvironment

Wang, Ji; Wang, Zi; Jia, Wenxue; Gong, Wei; Dong, Bokai; Wang, Zhuangzhuang; Zhou, Meng; Tian, Chao

doi:10.3389/fgene.2022.1024922

Cited by 7 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In gliomas, a unique expression profile of costimulatory molecules differentiates them from other cancers. Only six molecules—HHLA2, TNFRSF14, TNFRSF18, TNFRSF25, TNFRSF6B, and TNFSF9—are underexpressed in glioma tumors, while 48 others exhibit increased expression [ 12 ]. This differential expression significantly influences patient prognosis and therapeutic response, suggesting unique therapeutic opportunities.…”

Section: Main Textmentioning

confidence: 99%

See 1 more Smart Citation

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Regmi,

Wang,

Liu

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, the clinical outcomes have remained modest, with glioblastoma patients' median survival stagnating at less than 15 months. This underscores the urgent need for more specialized treatment strategies. Our review delves into the progression toward immunomodulation in glioma treatment. We dissect critical discoveries in immunotherapy, such as spotlighting the instrumental role of tumor-associated macrophages, which account for approximately half of the immune cells in the glioma microenvironment, and myeloid-derived suppressor cells. The complex interplay between tumor cells and the immune microenvironment has been explored, revealing novel therapeutic targets. The uniqueness of our review is its exhaustive approach, synthesizing current research to elucidate the intricate roles of various molecules and receptors within the glioma microenvironment. This comprehensive synthesis not only maps the current landscape but also provides a blueprint for refining immunotherapy for glioma, signifying a paradigm shift toward leveraging immune mechanisms for improved patient prognosis.

show abstract

Section: Main Textmentioning

confidence: 99%

“…This differential expression significantly influences patient prognosis and therapeutic response, suggesting unique therapeutic opportunities. Additionally, enrichment analyses revealed distinct correlations between costimulatory molecules and immunotherapy prediction pathways, underscoring their unique involvement in glioma biology [ 12 ].…”

Section: Main Textmentioning

confidence: 99%

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Regmi,

Wang,

Liu

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Although the advancement in medical technology has improved the early detection and bladder cancer treatment, its prognosis is still not optimistic owing to its recurrence rate and aggressiveness. [17][18][19] Therefore, it is important to find effective prognostic markers and establish accurate prognostic models for managing bladder cancer. Costimulatory molecules are important for the regulation of immune response, and they significantly influence the origin, growth and immune evasion of tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Bladder cancer is a prevalent cancer globally, with the highest incidence and fatality rates among cancers of the urinary system. Although the advancement in medical technology has improved the early detection and bladder cancer treatment, its prognosis is still not optimistic owing to its recurrence rate and aggressiveness 17–19 . Therefore, it is important to find effective prognostic markers and establish accurate prognostic models for managing bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

Exploration of the prognostic effect of costimulatory genes in bladder cancer

Su,

Liu,

Zhang

et al. 2024

The Journal of Gene Medicine

View full text Add to dashboard Cite

BackgroundA prognostic model of bladder cancer was constructed based on costimulatory molecules, and its stability and accuracy were verified in different datasets.MethodThe expression profile of bladder cancer RNA and the corresponding clinical data in The Cancer Genome Atlas (TCGA) database were analyzed employing computational biology, and a prognostic model was constructed for costimulating molecule‐related genes. The model was applied in GSE160693, GSE176307, Xiangya_Cohort, GSE13507, GSE19423, GSE31684, GSE32894, GSE48075, GSE69795 and GSE70691 in TCGA dataset and Gene Expression Omnibus database. The role of costimulating molecules in bladder cancer tumor subtypes was also explored. By consistent cluster analysis, bladder cancer in the TCGA dataset was categorized into two subtypes: C1 and C2. The C1 subtype exhibited a poor prognosis, high levels of immune cell infiltration and significant enrichment of natural killer cells, T cells and dendritic cells in the C1 subtype. In addition, the ImmuneScore calculated by the ESTIMATE algorithm differed greatly between the two subtypes, and the ImmuneScore of the C1 subtype was greater than the C2 subtype in a significant manner.ResultsThis study also assessed the relationship between costimulating molecules and immunotherapy response. The high‐risk group responded poorly to immunotherapy, with significant differences in the amount of most immune cells between the two groups. Further, three indices of the ESTIMATE algorithm and 22 immune cells of the CIBERSORT algorithm were significantly correlated with risk values. These findings suggest the potential value of costimulating molecules in predicting immunotherapy response.ConclusionA costimulatory molecule‐based prognostic model for bladder cancer was established and validated across multiple datasets. This model introduces a novel mode for tailoring treatments to each individual with bladder cancer, and offers valuable insights for informed clinical choices. Simultaneously, this research also delved into the significance of costimulating molecules within distinct bladder cancer subtypes, shedding novel insights into improving immunotherapy strategies for the treatment of bladder cancer.

show abstract

“…Apoptosis, or programmed cell death (PCD), 9 is critical in maintaining cellular homeostasis and integrity 10 . Dysregulated apoptotic pathways is a common feature of many cancers, including melanoma 11 .…”

Section: Introductionmentioning

confidence: 99%

The predictive efficacy of programmed cell death in immunotherapy of melanoma: A comprehensive analysis of gene expression data for programmed cell death biomarker and therapeutic target discovery

Yue,

Lian,

Duan

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

In this study, genes linked to prognosis in skin cutaneous melanoma (SKCM) involved in programmed cell death (PCD) were identified and confirmed and prognostic models based on these genes were constructed. Acquisition and analysis of clinical data and RNA sequencing information from The Cancer Genome Atlas‐SKCM (TCGA‐SKCM) and Sangerbox databases, gene expression data for 477 tumor samples and 2 normal samples were successfully gathered. The patients were separated into two clusters based on consensus clustering of PCD‐related genes, with Cluster A having greater tumor purity, ESTIMATE score, immune score, and matrix score, and Cluster B having a significantly distinct pattern of immune cell infiltration. The use of gene set enrichment analysis and weighted correlation network analysis showed significant associations between certain genes and factors such as tumor mutation burden, age, stage, grade, and tumor subtype. Finally, based on the 12 genes selected by Least Absolute Shrinkage and Selection Operator regression analysis (STAT3, IRF2, SLC7A11, ZEB1, LIPT1, PML, GCH1, GYS1, ABCC1, XBP1, TFAP2C, NOX4), a prognostic model of PGD‐related genes was constructed. The effectiveness of the model's prognostic value was confirmed through survival analysis, time‐dependent receiver operating characteristic curve, single‐factor Cox regression analysis, and nomogram. We also verified the relationship between the GCH1 and MKI67 expression by wet experiment. This model has high prediction accuracy in SKCM patients and can provide a reference for clinical treatment.

show abstract

The role of costimulatory molecules in glioma biology and immune microenvironment

Cited by 7 publications

References 34 publications

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Exploration of the prognostic effect of costimulatory genes in bladder cancer

The predictive efficacy of programmed cell death in immunotherapy of melanoma: A comprehensive analysis of gene expression data for programmed cell death biomarker and therapeutic target discovery

Contact Info

Product

Resources

About